TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6622929
Drug: Prednisolone plus
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone plus azathioprine 50 mg daily
Study: 30132529
Drug: Glucosamine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucosamine (2 g/day for 16 weeks)
Study: 27916140
Drug: Moderate alcohol
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Moderate alcohol consumption (2 cans of beer, 660 mL, ∼26 g alcohol)
Study: 25076468
Drug: Contralateral balanced
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contralateral balanced multifocal contact lens combination (CBMCLC)
Study: 22402677
Drug: Knee Outcome
Normalized name: Bos taurus knee joint preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Knee Outcome Survey activities of daily living subscale (KOS‐ADL)
Study: 19470315
Drug: Brief strategic
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brief strategic family therapy (BSFT)
Study: 2901181
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg once daily of methimazole
Study: 2901181
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg 3 times daily of methimazole
Study: 25182412
Drug: Real tVNS
Normalized name: TVN-102
DrugBank: TVN-102 (DB16990)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Real tVNS (transcutaneous vagus nerve stimulation) administered at left external acoustic meatus for 60 min
Study: 21575032
Drug: 5 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 μg TTX (given t.i.d.)
Study: 21575032
Drug: 10 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 μg TTX (given t.i.d.)
Study: 14499444
Drug: Topical morphine
Normalized name: morphine Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical morphine mouthwash (2 per thousand solution)
Study: 14499444
Drug: Topical morphine
Normalized name: morphine Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical morphine mouthwash (1 per thousand solution)
Study: 10872650
Drug: 10 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/kg ibuprofen lysine
Study: 9195171
Drug: 0.5% ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% ropivacaine 40 ml (200 mg)
Study: 9195171
Drug: 0.25% ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25% ropivacaine 40 ml (100 mg)
Study: 9195171
Drug: Saline 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline 40 ml
Study: 1287837
Drug: Continuous bupivacaine
Normalized name: Uniphyllin Continus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous bupivacaine infusion
Study: 1287837
Drug: Saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline infusion (Control) in patients with COAD
Study: 1287837
Drug: Continuous bupivacaine
Normalized name: Uniphyllin Continus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous bupivacaine infusion in patients with COAD
Study: 1287837
Drug: Saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline infusion (Control) in patients without COAD
Study: 4040887
Drug: pafenolol 25
Normalized name: atenolol 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: pafenolol 25 mg
Study: 4040887
Drug: pafenolol 50
Normalized name: atenolol 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: pafenolol 50 mg
Study: 20181302
Drug: Fluoxetine 20
Normalized name: fluoxetine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine 20 to 40 mg per day plus IPT adapted to BPD (IPT-BPD)
Study: 20181302
Drug: Fluoxetine 20
Normalized name: fluoxetine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine 20 to 40 mg per day plus clinical management
Study: 19060514
Drug: Intra-articular sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular sodium hyaluronate injections (Orthovisc)
Study: 11119731
Drug: Oral HRT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral HRT (2 mg of estradiol on days 1-12, 2 mg of estradiol plus 1 mg of norethisterone acetate on days 13-22, and 1 mg of estradiol on days 23-28; n = 21)
Study: 11119731
Drug: Transdermal HRT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal HRT (50 microg/d of estradiol on days 1-28 and 250 microg/d of norethisterone acetate on days 15-28; n = 21)
Study: 29125933
Drug: Rigid fixation
Normalized name: Pinus rigida pollen
DrugBank: Pinus rigida pollen (DB10896)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rigid fixation with 4 L miniplates placed bilaterally in the maxilla after distraction device removal.
Study: 28277060
Drug: Dual antiplatelet
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual antiplatelet therapy (DAPT) with clopidogrel in addition to aspirin
Study: 25516635
Drug: 3-weekly doses
Normalized name: selinexor
DrugBank: Selinexor (DB11942)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 3-weekly doses of nanoparticle albumin-bound paclitaxel
Study: 25516635
Drug: weekly doses
Normalized name: selinexor
DrugBank: Selinexor (DB11942)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: weekly doses of nanoparticle albumin-bound paclitaxel
Study: 25516635
Drug: weekly doses
Normalized name: selinexor
DrugBank: Selinexor (DB11942)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: weekly doses of Cremophor-based paclitaxel
Study: 18640467
Drug: Combination lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combination lidocaine 20 mg and dexamethasone 6 mg
Study: 14526299
Drug: 400 microg
Normalized name: Fentanyl 400 microgram buccal film
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 microg of oral misoprostol every 8 hours
Study: 14526299
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (oral and vaginal misoprostol)
Study: 18853315
Drug: Topical lomefloxacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical lomefloxacin 0.3%
Study: 6802100
Drug: Dextroamphetamine sulfate
Normalized name: Dextroamphetamine Sulfate
DrugBank: Dextroamphetamine (DB01576)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextroamphetamine sulfate (20 mg) after pimozide pretreatment (5 weeks)
Study: 6802100
Drug: Dextroamphetamine sulfate
Normalized name: Dextroamphetamine Sulfate
DrugBank: Dextroamphetamine (DB01576)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextroamphetamine sulfate (20 mg) after placebo pretreatment
Study: 6802100
Drug: Dextroamphetamine sulfate
Normalized name: Dextroamphetamine Sulfate
DrugBank: Dextroamphetamine (DB01576)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextroamphetamine sulfate (20 mg) after pimozide pretreatment
Study: 6802100
Drug: Dextroamphetamine sulfate
Normalized name: Dextroamphetamine Sulfate
DrugBank: Dextroamphetamine (DB01576)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextroamphetamine sulfate (20 mg)
Study: 30507214
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (CBT) anger-reduction treatment for 12 weeks
Study: 23340248
Drug: 0 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 g polydextrose (control)
Study: 23340248
Drug: 6.3 g
Normalized name: OCTINOXATE 6.3 g in 100 g TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6.3 g polydextrose
Study: 23340248
Drug: 12.5 g
Normalized name: glycerin 12.5 GM per 20.4 ML Enema
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12.5 g polydextrose
Study: 23340248
Drug: 25 g
Normalized name: AndroGel 1.25 g Packets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 g polydextrose
Study: 21079110
Drug: Extended arm
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extended arm (evidence-based practice bundle including omission of mechanical bowel preparation, preoperative and intraoperative warming, supplemental oxygen, intraoperative intravenous fluid restriction, use of a surgical wound protector)
Study: 17680178
Drug: Heparin anticoagulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin anticoagulation at 180 U x kg(‐1) plus 3000 U every 30 min for OPCAB patients, along with rectal aspirin 650 mg during the procedure.
Study: 17680178
Drug: Heparin anticoagulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin anticoagulation regimen in OPCAB patients.
Study: 17680178
Drug: Heparin and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin and protamine doses in OPCAB group.
Study: 10806855
Drug: Subcutaneous rhEpo
Normalized name: rhTPO
DrugBank: Recombinant Human Thrombopoietin (DB16364)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous rhEpo 150 U/kg.time, three times a week for 6 weeks
Study: 10806855
Drug: Subcutaneous rhEpo
Normalized name: rhTPO
DrugBank: Recombinant Human Thrombopoietin (DB16364)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous rhEpo 250 U/kg.time, three times a week for 6 weeks
Study: 7778529
Drug: Delapril 30
Normalized name: Delapril
DrugBank: Delapril (DB13312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delapril 30 mg twice daily
Study: 312976
Drug: Solu‐Medrol (methylprednisolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solu‐Medrol (methylprednisolone sodium succinate) 1 g/liter
Study: 24333889
Drug: Three months
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three months of drug therapy for comorbid mental disorders
Study: 10401950
Drug: CHDF circuit
Normalized name: BREATHING CIRCUIT W/MOUTHPIECE,STANDARD
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHDF circuit with a haemofilter made of polymethylmethacrylate membrane primed with 50 mg nafamostat in 500 ml saline, continuous injection of 0.5 mg/kg per h nafamostat, 700 ml/h of dialysis fluid and 1000 ml/h of filtrate fluid
Study: 2620043
Drug: Mebeverine (135
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mebeverine (135 mg, two capsules, three times daily)
Study: 2620043
Drug: Mefenamic acid
Normalized name: Mefenamic Acid
DrugBank: Mefenamic acid (DB00784)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mefenamic acid (250 mg, two capsules, three times daily)
Study: 2620043
Drug: Placebo (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (two capsules, three times daily)
Study: 1091532
Drug: Wheat bran
Normalized name: Wheat bran
DrugBank: Wheat bran (DB10685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wheat bran (20 g daily)
Study: 31021882
Drug: Serratus plane
Normalized name: Fucus serratus extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serratus plane block (SPB) with 25 ml of ropivacaine 0.5%
Study: 25478975
Drug: Remifentanil (0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil (0.75 μg/kg over 30 seconds)
Study: 25478975
Drug: Ketamine (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (0.25 mg/kg over 30 seconds)
Study: 25478975
Drug: Propofol (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (0.5 mg/kg over 30 seconds)
Study: 19483370
Drug: Vegetable tablets
Normalized name: Hydrogenated Vegetable Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vegetable tablets (10 g/trial)
Study: 19483370
Drug: Control tablets
Normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control tablets (10 g/trial)
Study: 11761819
Drug: Inhaled ambroxol
Normalized name: ambroxol
DrugBank: Ambroxol (DB06742)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled ambroxol
Study: 8131253
Drug: 15 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg/kg mefloquine
Study: 8131253
Drug: 25 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg/kg mefloquine
Study: 8131253
Drug: Quinine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinine (30 mg.kg‐1.day‐1) + Tetracycline (25 mg.kg‐1.day‐1) for re-treatment
Study: 2481671
Drug: Chemotherapy (specific
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (specific agents not detailed)
Study: 29046732
Drug: Group 1
Normalized name: Chlamydophila psittaci biogroup 1 Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 1 (G1): 300 g of vegetables and legumes containing on average 191 μg/day of folate and 1 hazelnut oil capsule
Study: 29046732
Drug: Group 2
Normalized name: Chlamydophila psittaci biogroup 2 Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 2 (G2): 300 g of vegetables and legumes containing on average 191 μg/day of folate and 1 placebo capsule
Study: 29046732
Drug: Group 3
Normalized name: Chlamydophila psittaci biogroup 3 Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 3 (G3): 300 g of vegetables and legumes containing on average 90 μg/day of folate and 1 hazelnut oil capsule
Study: 25305223
Drug: Riboflavin supplementation
Normalized name: Riboflavin
DrugBank: Riboflavin (DB00140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Riboflavin supplementation (10 mg/day)
Study: 8346830
Drug: Intravenous lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous lidocaine (0.5, 1.0, 1.5, or 2.0 mg/kg)
Study: 25147364
Drug: Intravenous lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous lidocaine (2 mg/kg)
Study: 31620802
Drug: 80 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg ixekizumab every 2 weeks for 12 weeks, then 80 mg open-label ixekizumab every 4 weeks through Week 52
Study: 31620802
Drug: Placebo for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for 12 weeks, then 80 mg open-label ixekizumab every 4 weeks through Week 52
Study: 30041702
Drug: Single intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intravenous dose of co-amoxiclav
Study: 26265075
Drug: Elastic Resistance
Normalized name: elastin
DrugBank: Elastin (human) (DB15364)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elastic Resistance Training (ERT) twice a week for 8 weeks
Study: 21410627
Drug: sitagliptin/metformin FDC
Approvals — FDA: no, EMA: no, PMDA: no
Description: sitagliptin/metformin FDC 50/500 mg bid
Study: 21410627
Drug: metformin monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: metformin monotherapy 500 mg bid (uptitrated to 1000 mg bid)
Study: 21410627
Drug: sitagliptin/metformin FDC
Approvals — FDA: no, EMA: no, PMDA: no
Description: sitagliptin/metformin FDC
Study: 23427864
Drug: metformin monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: metformin monotherapy
Study: 16532455
Drug: Gabapentin treatment
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gabapentin treatment (600-2,700 mg/day)
Study: 14612979
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg beta-carotene or lycopene supplementation
Study: 14612979
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg beta-carotene or lycopene supplementation
Study: 1346817
Drug: Standard heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard heparin (to achieve an activated partial thromboplastin time of 1.5 to 2.0 times the pretreatment value)
Study: 1346817
Drug: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight heparin (adjusted only for body weight) for 10 days
Study: 27553712
Drug: Oxytocin (24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxytocin (24 IU) administered intranasally
Study: 24471659
Drug: Intravenous parecoxib
Normalized name: parecoxib
DrugBank: Parecoxib (DB08439)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Intravenous parecoxib 40 mg then oral celecoxib 400 mg at 12 hours (group PC)
Study: 24471659
Drug: Intravenous paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous paracetamol 2 g then oral 1 g six-hourly (group PA)
Study: 24471659
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of intravenous parecoxib, oral celecoxib, and paracetamol (group PCPA)
Study: 22752297
Drug: Abiraterone acetate
Normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Abiraterone acetate (AA) 1,000 mg orally once daily + prednisone 5 mg orally twice daily
Study: 17676319
Drug: Voriconazole 400
Normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Voriconazole 400 mg twice daily on the first day and 200 mg twice daily on the second day
Study: 17676319
Drug: Fluconazole 400
Normalized name: fluconazole 400 MG in 200 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole 400 mg on the first day and 200 mg on the second day
Study: 12135535
Drug: 75 mg/d
Normalized name: Lyllana 0.075 MG/Day Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg/d venlafaxine
Study: 2332919
Drug: Diltiazem hydrochloride
Normalized name: Diltiazem Hydrochloride
DrugBank: Diltiazem (DB00343)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diltiazem hydrochloride (360 mg daily)
Study: 2332919
Drug: Propranolol hydrochloride
Normalized name: Propranolol Hydrochloride
DrugBank: Propranolol (DB00571)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propranolol hydrochloride (240 mg daily)
Study: 6774359
Drug: Thyrotropin-releasing hormone
Normalized name: thyrotropin-releasing hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyrotropin-releasing hormone (TRH), 0.5 mg i.v.
Study: 6774359
Drug: Thyroid hormones
Normalized name: Thyroid hormones
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyroid hormones (TH) pretreatment
Study: 6774359
Drug: Thyrotropin-releasing hormone
Normalized name: thyrotropin-releasing hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyrotropin-releasing hormone (TRH) with TH pretreatment
Study: 31405122
Drug: Lactobacillus gasseri
Normalized name: Lactobacillus Gasseri
DrugBank: Lactobacillus gasseri (DB16543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus gasseri CP2305 tablets
Study: 20727237
Drug: Fibre supplement
Normalized name: Fiore
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibre supplement (psyllium)
Study: 20727237
Drug: Healthy eating
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Healthy eating plus fibre supplement (HLT-FIB)
Study: 20727237
Drug: Fibre supplement
Normalized name: Fiore
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibre supplement (FIB)
Study: 19952360
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid (UDCA) treatment in men
Study: 19952360
Drug: Ursodeoxycholic acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ursodeoxycholic acid (UDCA) treatment in women
Study: 17161934
Drug: Standard preadmission
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard preadmission education (written educational material with non-systematic oral education) (Group B)
Study: 11157645
Drug: Low-intensity oral
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-intensity oral anticoagulant therapy (targeted INR of 2.5; range, 2.0 to 3.0)
Study: 11157645
Drug: IV heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV heparin
Study: 11157645
Drug: Heparin dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin dosage and age (> 70 years)
Study: 11157645
Drug: LMW heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: LMW heparin
Study: 3371392
Drug: Controlled-release metoprolol,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-release metoprolol, 100 mg once daily
Study: 22033512
Drug: Severe-light (S-L)
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Severe-light (S-L)
Study: 12920415
Drug: Typical antipsychotic
Normalized name: benzocaine Mucous Membrane Topical Solution [Topicale]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Typical antipsychotic discontinuation (n = 12)
Study: 12920415
Drug: Typical antipsychotic
Normalized name: benzocaine Mucous Membrane Topical Solution [Topicale]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Typical antipsychotic continuation (n = 12)
Study: 10902990
Drug: Energy supplement
Normalized name: Nutritional Supplement Oral Bar [PROTEIN FORTIFIED ENERGY SUPPLEMENT]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Energy supplement (E) = 1171 kJoule + 12 mg iron
Study: 10902990
Drug: Supplement (S)
Normalized name: S-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplement (S) = 104 kJ
Study: 1590284
Drug: Sustained-release morphine
Normalized name: morphine Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release morphine sulfate (SRMS) tablets, 30 mg every 12 hours
Study: 1590284
Drug: Immediate-release morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release morphine sulfate (IRMS) solution, same mg/24 hours dose, every 4 hours
Study: 1590284
Drug: Sustained-release morphine
Normalized name: morphine Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release morphine sulfate (SRMS) tablets
Study: 1590284
Drug: Immediate-release morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release morphine sulfate (IRMS) solution
Study: 12721256
Drug: Delayed Intensification
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed Intensification (DI) phase of therapy for 7 weeks
Study: 12721256
Drug: Delayed Intensification
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed Intensification (DI) phase of therapy
Study: 10474123
Drug: Pulsatile GnRH
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pulsatile GnRH infusion (100 ng/kg i.v. every 90 min for 2 weeks)
Study: 8709374
Drug: Transurethral resection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transurethral resection plus mitomycin C (20 mg/50 ml sodium chloride, every 2 weeks during year 1 and once a month during year 2)
Study: 8709374
Drug: Transurethral resection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transurethral resection plus bacillus Calmette-Guerin (BCG) (120 mg/50 ml sodium chloride, instilled once a week for 6 weeks and once a month for 4 months)
Study: 8709374
Drug: All therapy
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All therapy groups (mitomycin C, BCG, and transurethral resection only)
Study: 1855607
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg of intrapartum ampicillin intravenously
Study: 30794953
Drug: GnRH antagonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH antagonist protocol with HMG and low dose (100IU/day) hCG
Study: 30794953
Drug: Short GnRH-agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short GnRH-agonist protocol with HMG and low dose (100IU/day) hCG
Study: 28462571
Drug: Combined endurance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined endurance running and strength training program twice a week (ES60)